Abbott wins FDA approval for dual-energy ablation catheter
CEO Robert Ford has said the atrial fibrillation treatment, along with the company's Volt PFA device, is expected to help Abbott regain market share in electrophysiology.
Saúde Digital
9 notíciasAdvancements in Molecular Profiling and Impact on Cancer Care
NOW on demand, Part 1 of 3 Caris Life Sciences Series. Host Shahid Shah sits down with Dr. James Hamrick to start the series with, "The Science". The post Advancements in Molecular Profiling and Impact on Cancer Care appeared first on Health IT Answers.
NOW in Life Sciences – Month of August 2026
In this monthly report you will find news and highlights in the Applied Life Sciences from OSR Health, Clearmind Medicine, Kupando, Touchlight, ProBioGen, Celonic AG, Thrombolytic Science, Devonian Health Group, SpotitEarly, Neurizon® Therapeutics Limited, AlphaRose Therapeutics …
Faster, Safer Patient Care Starts With Better Team Chat – Healthcare IT Today
Faster, Safer Patient Care Starts With Better Team Chat Healthcare IT Today
Medtronic gets CE mark for ablation to treat ventricular tachycardia
Older ablation approaches for ventricular tachycardia have been suboptimal, Medtronic said. The company plans to bring a more effective treatment for the life-threatening heart condition.
Abbott starts TriClip study amid rising competition for heart valve repair
Facing competition from Edwards, Abbott is studying TriClip’s real-world safety and performance in about 1,000 patients.
AdvaMed Welcomes Key Developments in MDUFA VI Process
AdvaMed, the Medtech Association, welcomed next steps in the Medical Device User Fee Amendments reauthorization process following clearance by the White House Office of Management and Budget of the draft MDUFA VI agreement. The post AdvaMed Welcomes Key Developments in MDUFA VI …
J&J wins FDA approval for dual-energy ablation catheter
Johnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased commercial rollout.
Penumbra starts trial of clot removal device in stroke subgroup
Penumbra, which is set to become part of Boston Scientific this year, is running the trial to inform the treatment of a type of medium-vessel blockage.